UCLA and Caltech integrated Cardiovascular Medicine for Bioengineers (iCMB)

摘要 这个T32计划代表了一个新的模式，用于培训生物物理科学家和工程师， 心血管内科工程与医学的融合正在改变临床和患者 通过传感和成像的柔性电子技术的进步，再加上机器学习， 引入了新的创新，以应对不断上升的心脏代谢疾病的流行。大学 加州洛杉矶分校（UCLA）和加州理工学院（Caltech）正在合作开发 加州大学洛杉矶分校/加州理工学院综合心血管医学生物工程师（iCMB）计划，这将是 正式成为一个为期两年的结构化课程，重点是招聘代表性不足的职位， 博士工程师或生物物理科学家在学术界和工业界的领导作用。的方法 是加强1）高级传感或2）与机器结合的成像方面的个性化培训 学习处理心脏代谢疾病。iCMB计划将建立在两个成功的基础上 加州理工学院和加州大学洛杉矶分校联合培训计划：医学科学家培训计划（MSTP）的MD-PhD 学生和独特的专科培训和高级研究计划（星星）的奖学金水平 医生获得博士学位。与安进、约翰逊和约翰逊等行业领导者的合作伙伴关系， Medtronic和Edwards Lifesciences丰富了我们的实习、指导和领导力计划。 加州理工学院多样性中心和加州大学洛杉矶分校教师多样性与发展办公室都支持 为妇女和任职人数不足的妇女举办科学技术工程和数学讲习班 少数群体为了实施这个iCMB计划，我们开发了一个新的指导和自我评估 包括24名经验丰富的导师，4名新兴教师，22名临床教师（42%女性）和10名 行业领导者。每个iCMB学者将有共同导师：来自心脏代谢的主要导师 一个是医学，一个是使能技术或工业。在第一年，iCMB学者将开发 先进成像，传感器或计算的基础知识和道德教育培训， 生物医学研究和出版物。在第二年，iCMB学者将有一个选项1）参加一个 加州大学洛杉矶分校临床转化科学的临床和转化研究途径证书 研究所（CTSI）或FDA监管科学法律与技术（BE 188/299）;和/或2）参与 UCLA CTSI赞助的专业发展，为学术或行业职业生涯做准备。两 加州理工学院和加州大学洛杉矶分校院长已承诺为每个iCMB学者配套资金。加州大学洛杉矶分校的副教务长 研究生教育还承诺提供补充培训生支助，以提高培训生的多样性。 因此，加州理工学院/UCLA iCMB计划的互补和协同优势提供了一个新的 为解决全球流行的心脏代谢疾病而准备的劳动力注入。

ABSTRACT This T32 program represents a new paradigm for training biophysical scientists and engineers to traverse cardiovascular medicine. The convergence of engineering with medicine is transforming clinical and patient care via advances in flexible electronics for sensing and imaging, coupled with machine learning, which has introduced new innovations to confront the rising endemic of cardiometabolic disorders. The University of California at Los Angeles (UCLA) and the California Institute of Technology (Caltech) are partnering to develop the UCLA/Caltech integrated Cardiovascular Medicine for Bioengineers (iCMB) Program, that will be formalized into a 2-year, structured curriculum with an emphasis on recruiting the under-represented post- doctoral engineers or biophysical scientists into leadership roles in academia and industry. The approach is to strengthen individualized training in 1) advanced sensing or 2) imaging coupled with machine learning to address 3) cardiometabolic disease. The iCMB program will be built upon two successful Caltech and UCLA joint training programs: the Medical Scientist Training Program (MSTP) for MD-PhD students and the unique Subspecialty Training and Advanced Research Program (STAR) for fellowship-level physicians to obtain a PhD. The partnerships with the industry leaders from Amgen, Johnson & Johnson, Medtronic, and Edwards Lifesciences have enriched our internship, mentorship, and leadership programs. Both the Caltech Diversity Center and UCLA Faculty Diversity & Development Office have supported workshops on Science Technology Engineering & Mathematics (STEM) for women and under-represented minorities. To implement this iCMB Program, we have developed a novel mentoring and self-evaluating structure in the inclusion of 24 seasoned mentors, 4 emerging faculty, 22 Clinical Faculty (42% female), and 10 industry leaders. Each iCMB scholar will have co-mentorships: a primary mentor from cardiometabolic medicine and a secondary from enabling technologies or industry. In Year 1, iCMB scholars will develop fundamental knowledge in advanced imaging, sensors, or computation and didactic training for ethics in biomedical research and publications. In Year 2, iCMB scholar will have an option 1) to participate in a certificate in Pathways in Clinical and Translational Research from the UCLA Clinical Translational Science Institute (CTSI) or Law and Technology for FDA regulatory science (BE188/299); and/or 2) to participate in UCLA CTSI-sponsored professional development in preparation for an academic or industry career. Both Caltech and UCLA Deans have committed matching funds for each iCMB scholar. Our Vice Provost for UCLA Graduate Education has also committed supplemental trainee support to enhance the diversity of trainees. Therefore, the complementary and synergistic strengths of the Caltech/UCLA iCMB Program provide a new infusion of workforce prepared to solve the worldwide endemic of cardiometabolic disease.